Skip to main content
Top
Published in: Abdominal Radiology 1/2010

01-02-2010

Autoimmune hepatitis: CT and MR imaging features with histopathological correlation

Authors: V. Anik Sahni, Girish Raghunathan, Banafsche Mearadji, Chinweike Ukomadu, Jonathan Glickman, Stuart G. Silverman, Sukru M. Erturk, Koenraad J. Mortele

Published in: Abdominal Radiology | Issue 1/2010

Login to get access

Abstract

Background

To describe the CT and MRI features of autoimmune hepatitis (AIH) and correlate them with histological grade and stage. Observed changes associated with treatment are also described.

Methods

A retrospective analysis of the initial CT scans (n = 22) and MRI exams (n = 12) of 27 patients with pathologically-proven AIH was conducted. Multiple objective and subjective imaging features were evaluated. Correlation of imaging features with histological inflammatory grade and fibrotic stage was performed using the Fisher exact test and Spearman’s rank correlation coefficient. In eight patients serial CT and MR imaging during treatment was used to describe the changes associated with treatment.

Results

The presence of ascites, expanded gallbladder fossa, spleen size, and enlarged preportal space had significant positive correlations with fibrotic stage. No significant positive correlations existed between imaging features and portal or lobular inflammatory grade. Seven patients (25.9%) were normal. The most common abnormal finding was surface nodularity: CT (n = 11 [50%]) and MRI (n = 8 [66.7%]). There was a wide variability in imaging appearances of patients who had serial scans on treatment.

Conclusions

There is a wide spectrum of CT and MR imaging features in patients with AIH. Several MRI features demonstrate a significant positive correlation with fibrotic stage.
Literature
1.
go back to reference Waldenstrom J (1950) The diagnostic importance of ACTH. Acta Endocrinol (Copenh) 5:235–242 Waldenstrom J (1950) The diagnostic importance of ACTH. Acta Endocrinol (Copenh) 5:235–242
2.
go back to reference Czaja AJ (1995) Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 40:435–456CrossRefPubMed Czaja AJ (1995) Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 40:435–456CrossRefPubMed
3.
go back to reference Boberg KM, Aadland E, Jahnsen J, et al. (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33:99–103CrossRefPubMed Boberg KM, Aadland E, Jahnsen J, et al. (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33:99–103CrossRefPubMed
4.
go back to reference Wiesner RH, Demetris AJ, Belle SH, et al. (1998) Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28:638–645CrossRefPubMed Wiesner RH, Demetris AJ, Belle SH, et al. (1998) Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28:638–645CrossRefPubMed
5.
go back to reference Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497CrossRefPubMed Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497CrossRefPubMed
6.
go back to reference Mistilis SP, Skyring AP, Blackburn CRB (1968) Natural History of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med 17:214–223PubMed Mistilis SP, Skyring AP, Blackburn CRB (1968) Natural History of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med 17:214–223PubMed
7.
go back to reference Soloway R, Summerskill WHJ, Baggenstoss AH, et al. (1972) Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63:820–833PubMed Soloway R, Summerskill WHJ, Baggenstoss AH, et al. (1972) Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63:820–833PubMed
8.
go back to reference Czaja AJ, Carpenter HA (1993) Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832PubMed Czaja AJ, Carpenter HA (1993) Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832PubMed
9.
go back to reference Bilaj F, Hyslop WB, Rivero H, et al (2005) MR imaging findings in autoimmune hepatitis: correlation with clinical staging. Radiology 236:896–902CrossRefPubMed Bilaj F, Hyslop WB, Rivero H, et al (2005) MR imaging findings in autoimmune hepatitis: correlation with clinical staging. Radiology 236:896–902CrossRefPubMed
10.
go back to reference Qayyum A, Graser A, Westphalen A, et al (2004) CT of benign hypervascular nodules in autoimmune hepatitis. AJR Am J Roentgenol 183:1573–1576PubMed Qayyum A, Graser A, Westphalen A, et al (2004) CT of benign hypervascular nodules in autoimmune hepatitis. AJR Am J Roentgenol 183:1573–1576PubMed
11.
go back to reference Giorgio A, Amoroso P, Lettieri G, et al (1986) Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. Radiology 161:443–445PubMed Giorgio A, Amoroso P, Lettieri G, et al (1986) Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. Radiology 161:443–445PubMed
12.
go back to reference Batts K, Ludwig J (1995) Chronic Hepatitis. An update on terminology and reporting. Am J Surg Pathol 19:1409–1417PubMedCrossRef Batts K, Ludwig J (1995) Chronic Hepatitis. An update on terminology and reporting. Am J Surg Pathol 19:1409–1417PubMedCrossRef
14.
go back to reference Czaja AJ, Carpenter HA (1993) Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824PubMed Czaja AJ, Carpenter HA (1993) Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824PubMed
15.
go back to reference Johnson PJ, McFarlane IG (1993) Meeting report: international autoimmune hepatitis group. Hepatology 18:998–1005CrossRefPubMed Johnson PJ, McFarlane IG (1993) Meeting report: international autoimmune hepatitis group. Hepatology 18:998–1005CrossRefPubMed
16.
go back to reference Alvarez F, Berg PA, Bianchi FB, et al. (1999) International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938CrossRefPubMed Alvarez F, Berg PA, Bianchi FB, et al. (1999) International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938CrossRefPubMed
17.
go back to reference Dodd GD III, Baron RL, Oliver JH III, Federle MP (1999) Spectrum of imaging findings of the liver in end-stage cirrhosis. I. Gross morphology and diffuse abnormality. AJR Am J Roentgenol 173:1031–1036PubMed Dodd GD III, Baron RL, Oliver JH III, Federle MP (1999) Spectrum of imaging findings of the liver in end-stage cirrhosis. I. Gross morphology and diffuse abnormality. AJR Am J Roentgenol 173:1031–1036PubMed
18.
go back to reference Dodd GD III, Baron RL, Oliver JH, Federle MP (1999) Spectrum of imaging findings of the liver in end-stage cirrhosis. II. Focal abnormalities. AJR Am J Roentgenol 173:1185–1192PubMed Dodd GD III, Baron RL, Oliver JH, Federle MP (1999) Spectrum of imaging findings of the liver in end-stage cirrhosis. II. Focal abnormalities. AJR Am J Roentgenol 173:1185–1192PubMed
19.
go back to reference Dodd GD III, Baron RL, Oliver JH III, Federle MP (1999) Hepatic morphology in end-stage primary sclerosing cholangitis: computed tomographic findings in 36 patients. Radiology 211:357–362PubMed Dodd GD III, Baron RL, Oliver JH III, Federle MP (1999) Hepatic morphology in end-stage primary sclerosing cholangitis: computed tomographic findings in 36 patients. Radiology 211:357–362PubMed
20.
go back to reference Feld JJ, Dinh H, Arenovich T, et al. (2005) Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42:53CrossRefPubMed Feld JJ, Dinh H, Arenovich T, et al. (2005) Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42:53CrossRefPubMed
21.
go back to reference Murray-Lyon IM, Stern RB, Williams R (1973) Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1:735–737CrossRefPubMed Murray-Lyon IM, Stern RB, Williams R (1973) Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1:735–737CrossRefPubMed
22.
go back to reference Cook GC, Mulligan R, Sherlock S (1971) Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40:159–185PubMed Cook GC, Mulligan R, Sherlock S (1971) Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40:159–185PubMed
23.
go back to reference Roberts SK, Theneau T, Czaja AJ (1996) Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110:848–857CrossRefPubMed Roberts SK, Theneau T, Czaja AJ (1996) Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110:848–857CrossRefPubMed
24.
go back to reference Luxon B (2008) Diagnosis and treatment of autoimmune hepatitis. Gastroenterol Clin N Am 37:461–478CrossRef Luxon B (2008) Diagnosis and treatment of autoimmune hepatitis. Gastroenterol Clin N Am 37:461–478CrossRef
25.
go back to reference Cassani F, Valentini P, Cataleta M, et al. (1997) Ultrasound-detected abdominal lymphadenopathy in chronic hepatitis C: high frequency and relationship with viremia. J Hepatol 26:479–483CrossRefPubMed Cassani F, Valentini P, Cataleta M, et al. (1997) Ultrasound-detected abdominal lymphadenopathy in chronic hepatitis C: high frequency and relationship with viremia. J Hepatol 26:479–483CrossRefPubMed
26.
go back to reference Blachar A, Federle MP, Brancatelli G (2001) Primary biliary cirrhosis: clinical, pathological, and helical CT findings in 53 patients. Radiology 220:329–336PubMed Blachar A, Federle MP, Brancatelli G (2001) Primary biliary cirrhosis: clinical, pathological, and helical CT findings in 53 patients. Radiology 220:329–336PubMed
27.
go back to reference Park SZ, Nagorney DM, Czaja AJ (2000) Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 45:1944–1948CrossRefPubMed Park SZ, Nagorney DM, Czaja AJ (2000) Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 45:1944–1948CrossRefPubMed
28.
go back to reference Yin M, Talwalkar JA, Glaser KJ, et al (2007) Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 5:1207–1213CrossRefPubMed Yin M, Talwalkar JA, Glaser KJ, et al (2007) Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 5:1207–1213CrossRefPubMed
29.
go back to reference Lewin M, Poujol-Robert A, Boelle P-Y, et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46:658–665CrossRefPubMed Lewin M, Poujol-Robert A, Boelle P-Y, et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46:658–665CrossRefPubMed
Metadata
Title
Autoimmune hepatitis: CT and MR imaging features with histopathological correlation
Authors
V. Anik Sahni
Girish Raghunathan
Banafsche Mearadji
Chinweike Ukomadu
Jonathan Glickman
Stuart G. Silverman
Sukru M. Erturk
Koenraad J. Mortele
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 1/2010
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-008-9485-4

Other articles of this Issue 1/2010

Abdominal Radiology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine